Introduction {#s1}
============

A strong link exists between insufficient sleep and weight gain. A study of more than 30,000 participants found that those who slept less than 6 hr per night were more likely to gain weight over a 1-year period compared to people who slept 7 to 8 hr per night ([@bib24]). Moreover, when healthy adults obtain insufficient sleep (i.e., 5 hr per night) they are more likely to consume weight-promoting foods compared to persons who obtain sufficient sleep (i.e., 9 hr per night; [@bib11]). Rapid eye movement (REM) sleep loss itself may be sufficient to increase consumption of weight promoting, highly palatable foods (HPF). [@bib20] found that REM sleep loss in humans, over a period of 5 d, was inversely associated with hunger ratings and fat consumption. Indeed, increased intake of weight promoting, highly palatable foods may, over time, lead to adverse health outcomes such as obesity, diabetes and cardiovascular diseases.

Several studies have attempted to uncover the underlying neural mechanisms responsible for mediating an increased desire to consume HPF in response to sleep deprivation. Healthy adults who were subjected to one night of total sleep loss reported an increased desire to consume high-calorie foods compared to non-sleep deprived controls ([@bib4]). In addition, sleep deprivation decreased activation, assessed by fMRI scans, in areas of the brain thought to mediate reward anticipation and inhibitory control, namely the anterior cingulate and orbitofrontal cortex, respectively ([@bib4]; [@bib10]; [@bib23]). However, the relationship between brain function and sleep loss are not consistent. For example, presentation of HPF to sleep deprived healthy adults was not associated with anterior cingulate activation ([@bib21]) while in other instances a positive association was found between appetite for HPF and anterior cingulate function ([@bib1]).

Therefore, the current investigation sought to determine the role of the medial prefrontal cortex (medial PFC, mPFC) in mediating appetite for highly palatable foods in mice experiencing REM sleep loss. To achieve this aim, we used a well-validated chemogenetic method ([@bib8]) to produce a modified invertebrate chloride channel (GluClαβ) that when activated by the drug ivermectin (IVM) facilitates neuronal inhibition in the mPFC over several days. We then examined the effect of mPFC inactivation and REM sleep loss on appetite for HPF in mice.

Results {#s2}
=======

Wire-mesh-grid device exposure produced REM sleep loss {#s2-1}
------------------------------------------------------

During the dark period, mice exposed to a wire-mesh-grid device (WMGD) in their housing cage ([Figure 1A](#fig1){ref-type="fig"}) over a 72-hr period showed significantly less REM sleep after device introduction compared to baseline polygraphic recordings obtained without the device (F~3,6~ = 23.835, p = 0.001; [Figure 1B and C](#fig1){ref-type="fig"}, [@bib12]). There was a significant REM sleep reduction of 58% observed between baseline and the 25--48 hr dark time period (p = 0.026) and a 56% REM sleep reduction observed between baseline and the 49--72 hr dark time period (p = 0.020). In addition, a 46% REM sleep reduction was found when comparing the 0--24 hr and 25--48 hr dark time periods (p = 0.009). Moreover, we did not observe any rebound in REM sleep during the first 3 hr of the 25--48 hr light period (all comparisons p \> 0.05; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). A significant increase in wakefulness was also produced by the device during the dark period (F~3,6~ = 6.886, p = 0.023). Specifically, a 23% increase in wakefulness during the dark period was observed between baseline and the 49--72 hr time period (p = 0.042). No differences were observed between time periods, during the dark phase, for slow-wave sleep (SWS)---also known as non-REM sleep---(F~3,6~ = 4.605, p = 0.053). In addition, differences between time periods, during the light phase, for wake (F~3,6~ = 1.608, p = 0.284), REM (F~3,6~ = 1.103, 0.418) and SWS (F~3,6~ = 1.434, p = 0.323) were also non-significant.10.7554/eLife.20269.002Figure 1.A wire-mesh-grid device (WMGD) produced REM sleep loss during the dark period in mice.(**A**) A pictorial representation of the WMGD (left) and the housing cage in which the WMGD was placed (right). (**B** and **C**) Time-courses (25--48 hr) of slow wave sleep (SWS), REM sleep and wake (**B**) and time spent in each sleep stage (**C**). Black and white bars in (**B**) indicate dark and light period, respectively. \*p \< 0.05 and \*\*p \< 0.01 indicate significant differences between baseline and WMGD exposure (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.20269.002](10.7554/eLife.20269.002)10.7554/eLife.20269.003Figure 1---figure supplement 1.REM sleep does not rebound during the light phase in mice exposed to the WMGD for 25--48 hr compared to baseline. REM, Rapid eye movement.**DOI:** [http://dx.doi.org/10.7554/eLife.20269.003](10.7554/eLife.20269.003)

Exposing mice to the WMGD significantly affected sleep episode numbers during the 25--48 hr light and dark periods ([Figure 2A](#fig2){ref-type="fig"}). Specifically, WMGD exposure increased the number of SWS episodes during the light period, lasting 120 to 239 s, by 44% compared to baseline measures taken without the WMGD (t~2~ = −18.898, p = 0.003). Furthermore, WMGD exposure decreased the number of REM episodes during the dark period, lasting 60 to 119 s, by 69% compared to baseline (t~2~ = 9.430, p=0.011). On the other hand, WMGD exposure increased the number of wake episodes during the light period, lasting 30 to 59 s, by 42% compared to baseline (t~2~ = −4.355, p = 0.049). The mean duration of SWS, REM sleep and wake episodes was not significantly different after WMGD exposure ([Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.20269.004Figure 2.Sleep-wake profiles under baseline and wire-mesh-grid device (WMGD) conditions in mice for a 25--48 hr period, assessed by EEG/EMG recordings.(**A** and **B**) Effect of the WMGD on episode number (**A**) and duration (**B**) of slow wave sleep (SWS), REM sleep and wake during the light and dark phases. \*p \< 0.05 and \*\*p \< 0.01, indicates significant differences between baseline and WMGD exposure (n = 3). (**C**) EEG power density of SWS and REM sleep episodes in the light and dark phases. \# and \* symbols indicate significant differences (p \< 0.01) between baseline and WMGD exposure during light (\#) and dark phases (\*).**DOI:** [http://dx.doi.org/10.7554/eLife.20269.004](10.7554/eLife.20269.004)

SWS electroencephalogram (EEG) power density was also affected by WMGD exposure during the 25--48 hr light and dark periods ([Figure 2C](#fig2){ref-type="fig"}). That is, we observed increases in SWS EEG power density, of 12% to 14%, after exposure to the WMGD during the light period at 2.5 Hz (t~2~ = −51.786, p = 0.000), 22 Hz (t~2~ = −49.829, p = 0.000) and 24 Hz (t~2~ = −31.982, p = 0.001) compared to baseline. We also observed increases in SWS EEG power density, of 12% to 14%, after WMGD exposure during the dark period at 2.5 Hz (t~2~ = −42.819, p = 0.001), 3 Hz (t~2~ = −27.978, p = 0.001), 10.5 Hz (t~2~ = −121.636, p = 0.000) and 11 Hz (t~2~ = −46.198, p = 0.000) compared to baseline. On the other hand, we did not observe significant differences in REM EEG power density during the 25--48 hr light or dark period (all comparisons p \> 0.05; [Figure 2](#fig2){ref-type="fig"}, Panel C).

These results suggest that REM sleep is specifically reduced during the dark period in mice after WMGD exposure for the 25--48 hr time period, or longer, and thus the WMGD may be useful to elucidate the role of REM sleep loss on HPF consumption.

GluClαβ-mPFC neuronal inhibition reverses the effect REM sleep loss on HPF consumption {#s2-2}
--------------------------------------------------------------------------------------

Next, we investigated the effect of REM sleep loss on HPF consumption and whether changes in the latter one depend on the mPFC. Therefore, we used a chemogenetic system that involves a *Caenorhabditis elegans* glutamate-gated and IVM-gated chloride channel that was mutagenically modified to abolish sensitivity to glutamate while retaining sensitivity to IVM ([@bib8]). The altered heteromeric channel, which is made up of an α-subunit and β-subunit, prevents the firing of action potentials by hyperpolarizing the cell membrane for several days after administration of IVM.

Two adeno-associated viruses (AAV) carrying the α-subunit or β-subunit of the IVM-gated GluClαβ channel (AAV-GluClα-IVM and AAV-GluClβ-IVM) were stereotaxically co-injected bilaterally into the mPFC of wild-type mice ([Figure 3A and B](#fig3){ref-type="fig"}). To detect expression of the GluClαβ channel, we labeled neurons with anti-green fluorescent protein (GFP) antibodies to stain the fusion proteins of the GluClα-subunit and GluClβ-subunit with yellow and cyan fluorescent proteins, respectively. Heat maps depicting AAV location and spread within the mPFC are displayed in [Figures 3B](#fig3){ref-type="fig"} and [4A](#fig4){ref-type="fig"}. The virus successfully targeted the mPFC, for mice used in all experiments, including the cingulate, prelimbic and infralimbic cortices ([Figure 3B](#fig3){ref-type="fig"}). IVM-injected mice had markedly attenuated Fos expression in the mPFC compared to mice injected with propylene glycol, indicating that the GluClαβ successfully inhibited neuronal activity in the mPFC ([Figure 3C](#fig3){ref-type="fig"}). SWS, REM and wakefulness amounts were non-significant when comparing the light and dark phases during the 25--48 hr time period for mPFC inactivated mice to the light and dark phases of the baseline day before the IVM injection ([Figure 3D](#fig3){ref-type="fig"}; all comparisons p\>0.05).10.7554/eLife.20269.005Figure 3.Chemogenetic inhibition of medial prefrontal cortex (mPFC) neurons in mice.(**A**) Wild-type mice were injected with GluClα-IVM and GluClβ-IVM adeno-associated viruses (AAV; left) into the mPFC and implanted with somnographic electrodes (right). (**B**) Brain sections were stained against fluorescent protein (GFP) to confirm that GluClα and GluClβ proteins were expressed in the mPFC. Scale bar: 500 μm (left). Drawings of superimposed AAV injection sites in the mPFC are shown on the right (n = 3). (**C**) GFP (brown) and Fos (black) expression in two mice injected with AAV-GluClα-IVM and AAV-GluClβ-IVM into the mPFC and treated with propylene glycol (PG) or ivermectin (IVM). Scale bars: 20 μm. Blue and black arrows indicate neurons expressing GFP and Fos, respectively. (D) Time spent in slow wave sleep (SWS), REM sleep and wake between 25--48 hr after IVM treatment in mice injected with AAV-GluClα-IVM/AAV-GluClβ-IVM into the mPFC. Other abbreviations: ITR, inverted terminal repeat; CMV, cytomegalovirus; SV40, simian virus 40; EYFP, enhanced yellow fluorescent protein; ECFP, enhanced cyan fluorescent protein; Cg1, cingulate cortex; PrL, prelimbic cortex; IL, infralimbic cortex; DP, dorsal peduncular cortex.**DOI:** [http://dx.doi.org/10.7554/eLife.20269.005](10.7554/eLife.20269.005)10.7554/eLife.20269.006Figure 4.Chemogenetic inhibition of medial prefrontal cortex (mPFC) neurons reverses the effect of REM sleep loss on highly-palatable-foods consumption.(**A**) Drawings of superimposed adeno-associated viruses (AAV) injection sites in the mPFC of mice used for baseline (n = 3; left panel) or wire-mesh-grid device (WMGD) experiments \[n = 4 in the propylene glycol (PG), middle panel, or ivermectin (IVM), right panel, treated group\]. (B) Grams of sucrose or fat consumed over a 25--48 hr period under baseline (nine wild-type mice treated with saline and three AAV-injected mice treated with PG) and WMGD \[AAV-injected mice treated with PG (n = 4) or IVM (n = 4)\] conditions. \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 indicates significant differences between mice groups (one-tailed).**DOI:** [http://dx.doi.org/10.7554/eLife.20269.006](10.7554/eLife.20269.006)10.7554/eLife.20269.007Figure 4---figure supplement 1.Control experiments for highly palatable foods consumption in mice.(**A**) Grams of sucrose or fat consumed over a 25--48 hr period for wild-type mice treated with saline (n = 9) or AAV-injected mice treated with PG (n = 3) compared to AAV-injected mice treated with IVM (n = 4). (**B**) Grams of sucrose or fat consumed over a 25--48 hr period correlated with baseline body weight in grams for all mice.**DOI:** [http://dx.doi.org/10.7554/eLife.20269.007](10.7554/eLife.20269.007)

We then examined the effect of REM sleep loss on sucrose consumption and whether changes in sucrose consumption depend on the mPFC (F~3,16~ = 3.206, p = 0.051; see [Figure 4](#fig4){ref-type="fig"}, Panel B). We compared non-sleep deprived mPFC inactivated mice to non-sleep deprived control mice and found no difference between these groups in sucrose (propylene glycol injected mice: p = 0.391; saline injected mice: p = 0.350) or fat consumption (propylene glycol injected mice: p = 0.575; saline injected mice: p = 0.434); indicating that mPFC inactivation, alone, did not affect sucrose or fat consumption in mice ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, Panel A). Moreover, we found that REM sleep loss increased sucrose consumption by 27% compared to non-sleep deprived saline injected controls (p = 0.039) and 35% compared to non-sleep deprived propylene glycol injected controls (p = 0.033). On the other hand, mPFC neuronal inhibition reversed the effect of REM sleep loss on sucrose consumption. Specifically, mPFC inactivated, REM sleep deprived mice consumed 49% less sucrose compared to REM sleep deprived controls (p = 0.004). Whereas sucrose consumption was non-significant between mPFC inactivated, REM sleep deprived mice and non-sleep deprived propylene glycol injected (p = 0.205) and saline injected controls (p=0.060).

Furthermore, the effect of REM sleep loss on fat consumption was also examined and whether changes in fat consumption depend on the mPFC (F~3,16~ = 7.778, p = 0.002; see [Figure 4](#fig4){ref-type="fig"}, Panel B). We found that REM sleep loss increased fat consumption by 26% compared to non-sleep deprived saline injected controls (p = 0.001) and 35% compared to non-sleep deprived propylene glycol injected controls (p = 0.000). However, mPFC inhibition paired with REM sleep loss did not affect fat consumption compared to sleep deprived controls (p = 0.199).

Baseline and follow-up weights of mice in the non-sleep deprived saline injected, non-sleep deprived propylene glycol injected, REM sleep reduced and mPFC inactivated groups were non-significant (Baseline: F~3,16~ = 0.414, p = 0.745; Follow-up: F~3,16~ = 0.538, p = 0.663). In addition, body weight did not significantly change between baseline and follow-up time points for the non-sleep deprived saline injected mice (t~8~ = 0.468, p = 0.652), non-sleep deprived propylene glycol injected mice (t~2~ = 0.756, p = 0.529), REM sleep reduced (t~3~ = 0.157, p = 0.885) or PFC inactivated groups (t~3~ = 0.001, p = 0.999). Finally, the amounts of sucrose (r = −0.175, p = 0.400) and fat (r = 0.246, p =0.240) consumed were not associated with baseline body weight ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, Panel B).

Discussion {#s3}
==========

We were successfully able to mitigate the increased consumption of sucrose that resulted from REM sleep loss. We achieved this aim by chemogenetically inhibiting mPFC function. These results are the first to demonstrate a clear, causative link between mPFC function, REM sleep and HPF consumption. Specifically, REM sleep loss increased consumption of two highly palatable foods, namely sucrose and fat. Whereas, mPFC inhibition completely reversed increased sucrose intake by attenuating the effect of REM sleep loss on sucrose consumption. On the other hand, mPFC inhibition did not attenuate the effect of REM sleep loss on fat consumption.

The PFC appears to play a role in mediating goal directed behavior toward highly appetitive food stimuli. Brain circuits responsible for judging the palatability of foods such as taste, texture and smell are mediated by areas of the PFC including the orbitofrontal and anterior cingulate cortex ([@bib18]). More specifically, the anterior cingulate appears to mediate taste for glucose in primates as feeding fruit juice (i.e., a high-glucose food) to satiety decreased neuronal firing in the anterior cingulate cortex using single cell recordings, whereas initial juice feeding increased neuronal firing in these animals ([@bib17]). Chocolate flavor also increases activation, as measured by fMRI, in the anterior cingulate cortex in humans ([@bib16]). In addition, obese patients display increased PFC activity in response to high-calorie visual food stimuli; specifically, increased activity in the orbitofrontal and anterior cingulate cortex ([@bib22]; [@bib19]). Alterations in PFC brain activity may, over time, result in the inability of these persons to inhibit salient food cues leading to excess high calorie food consumption and weight gain. Our results support these data by directly manipulating mPFC function in mice, which resulted in a substantial decrease in sucrose consumption, but had no effect on fat consumption. On the other hand, it is unknown whether consumption of other highly palatable foods may be effected by mPFC inactivation and/or REM disruption (e.g., foods high in salt content). Future research is needed to explore this possibility. The mPFC contains heterogeneous neurons that include some inhibitory GABAergic interneurons (approximately 20%) and excitatory pyramidal neurons (approximately 80%; ([@bib15]). Moreover, mPFC neurons expressing dopamine D1 receptors mediate food consumption ([@bib6]); however, it is currently unknown what role this neuronal subtype may play in controlling highly palatable food consumption in response to REM sleep disruption.

Furthermore, in humans REM sleep loss adversely affects dietary behavior which may lead to weight gain. For example, REM sleep loss in humans enhances the desire to consume food and increases food consumption ([@bib3]; [@bib20]). In addition, REM sleep loss in children and adolescents, of 1 hr per night measured over three nights, was associated with a marked increase in the likelihood of these children being overweight ([@bib9]). In agreement with these findings, we observed that reducing REM sleep, over a 25--48 hr period, during the dark phase resulted in increased HPF consumption. On the other hand, it should be noted that, in the current investigation, REM sleep was not effected during the light phase. It is unknown why our observed reduction in REM sleep was restricted to the dark phase and not during the light phase. Indeed, sleep pressure is greater during the light phase compared to the dark phase in mice; therefore, it is possible that our device was only able to produce REM reduction during the dark phase when sleep pressure was weaker. In addition, the REM sleep disruption observed in the current investigation did not occur during the first 24 hr after WMGD introduction. A plausible explanation is that the sleep reducing effect of our device requires time to build-up and thus produce disturbances in sleep.

In conclusion, our results demonstrated that mPFC inhibition reduced sucrose consumption in REM sleep deprived mice. Our results clearly indicate that increased HPF consumption, resulting from REM sleep loss, is mediated by mPFC function thereby providing clear findings that elucidate the role of the mPFC and REM sleep loss in mediating unhealthy dietary behavior, which may lead to adverse health outcomes.

Materials and methods {#s4}
=====================

Subjects and chemicals {#s4-1}
----------------------

A male mouse line on a C57BL/6 background, which was maintained at the International Institute of Integrative Sleep Medicine and weighed between 23 and 34 g (9--10 weeks old) at the beginning of the experiments, was used for all experiments. The animals were individually housed in insulated sound-proof chambers maintained at an ambient room temperature of 22°C ± 1°C with a relative humidity of 60 ± 2% in an automatically controlled 12 hr light/dark cycle (lights on at 8:00, lights off at 20:00). Food and water were available *ad libitum*. No method of blinding or randomization was used for any of the experiments. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols (\#16--359) of the University of Tsukuba. All protocols aimed to reduce the number of animals used for each experiment and to minimize pain or discomfort. IVM was obtained from Merial Company.

AAV vector generation {#s4-2}
---------------------

The AAV of serotype rh10 for AAV10-α-GluCl-IVM-EYFP (AAV-GluClα-IVM) and AAV10-β-GluCl-IVM-ECFP (AAV-GluClβ-IVM) were generated by tripartite transfection (AAV-rep2/caprh10 expression plasmid, adenovirus helper plasmid, and pAAV-GluClα-IVM or pAAV-GluClβ-IVM plasmid) into 293A cells. After 3 days, 293A cells were resuspended in artificial cerebrospinal fluid (aCSF), freeze-thawed four times, and treated with benzonase nuclease (Millipore) to degrade all forms of DNA and RNA. Subsequently, the cell debris was removed by centrifugation and the virus titre in the supernatant was determined using an AAVpro Titration Kit for Real Time PCR (Takara) (See [Figure 3](#fig3){ref-type="fig"}, Panel A).

Stereotaxic AAV injection and placement of EEG/EMG electrodes {#s4-3}
-------------------------------------------------------------

Surgeries for AAV injections were conducted under pentobarbital anaesthesia (50 mg/kg, intraperitoneal \[i.p.\]). Using aseptic techniques, mice were injected stereotaxically into the mPFC (n = 14) with recombinant GluClα-AAV and GluClβ-AAV (250 nl/injection, 1.1 × 10^11^ particles/ml), with a glass micropipette and an air pressure injector system ([@bib2]). The following coordinates were used for injections into the mPFC of C57BL/6 mice according to the atlas of [@bib14]. Bilateral injections were made at 1.7 mm anterior and 0.4 mm lateral to bregma, and 2.0 mm below the dural surface.

Mice were also chronically implanted with EEG and electromyogram (EMG) electrodes for polysomnography (n = 6) as previously outlined ([@bib13]). Briefly, the implant comprised two stainless steel screws (1 mm diameter) serving as EEG electrodes, one of which was placed epidurally over the right frontal cortex (1.0 mm anterior and 1.5 mm lateral to bregma) and the other over the right parietal cortex (1.0 mm anterior and 1.5 mm lateral to lambda). Two insulated Teflon-coated, silver wires (0.2 mm in diameter), which were placed bilaterally into the trapezius muscles, served as EMG electrodes. Both EEG and EMG electrodes were connected to a microconnector, and the whole assembly was then fixed to the skull with self-curing dental acrylic resin. Animals were allowed one week for postoperative recovery before being placed in experimental housing cages ([Figure 1](#fig1){ref-type="fig"}, Panel A) for a 24 hr habituation period and connected with recording leads.

EEG/EMG recording {#s4-4}
-----------------

After the 24-hr habituation period, mice were injected with vehicle (propylene glycol, i.p.) at 16:30. Baseline polygraphic recording commenced at 17:00 and terminated at 16:00 the following day. After baseline recordings were obtained, mice (n = 3) were injected with IVM (10 mg/kg; i.p.) at 16:30 on the following day to initiate virus activation. Polygraphic recordings subsequently commenced at 17:00 for a period of 72 hr.

A separate group of EEG/EMG implanted mice (n = 3) were tested using the preceding methods with the exception that mice did not receive AAV infusions and did not receive i.p. injections. Instead, a wire-mesh-grid cage bottom (purchased from Oriental Yeast Company, Tokyo, Japan) was introduced, at 16:30 the day after baseline polygraphic recording, for a period of 72 hr. The wire-mesh-grid cage bottom was constructed from stainless steel and measured: 22 cm (length) × 19.5 cm (width) × 2.5 cm (height) with the grid consisting of 1 cm^2^ openings (see [Figure 1](#fig1){ref-type="fig"}, Panel A).

Vigilance state assessment based on EEG/EMG/locomotor activity recordings {#s4-5}
-------------------------------------------------------------------------

The EEG/EMG signals were amplified and filtered (EEG: 0.5--64 Hz, EMG: 16--64 Hz), then digitised at a sampling rate of 128 Hz, and recorded using SLEEPSIGN software ([@bib5]) (Kissei Comtec). In addition, locomotor activity was recorded with an infrared photocell sensor (Biotex). The vigilance states were scored offline by 10 s epochs into three stages, including waking, SWS, and REM sleep, according to standard criteria ([@bib13]). As a final step, defined vigilance stages were examined visually, and corrected when necessary.

HPF data collection {#s4-6}
-------------------

HPF consumption measurements were obtained from mice that did not receive EEG/EMG electrode implantation (n = 24). After AAV infusion, mice were singly placed into testing cages without the wire-mesh-grid-cage bottoms for 7 days. During these seven days mice had free access to laboratory chow. On day 8, mice were injected with IVM (10 mg/kg, i.p.; n = 4) or vehicle (propylene glycol; n = 4) at 16:30 and singly placed back into their housing cages with the addition of the wire-mesh-grid cage bottoms at 17:00 ([Figure 1](#fig1){ref-type="fig"}, Panel A). The highly palatable foods were introduced on day 8 and food consumption was subsequently measured every 24 hr at 17:00 over a total period of 72 hr. In addition, three controls groups were used in which one group of mice did not receive AAV infusions and were injected with saline (n = 9), one group of mice received AAV infusions and were injected with propylene glycol (n = 3), and one group of mice received AAV infusions and were injected with IVM (n = 4). All three groups were not exposed to the wire-mesh-grid cage bottom (i.e., the non-sleep deprived groups). During the 72 hr test period, all mice had free access to white chocolate (DARS brand, Morinaga Company, Tokyo, Japan), a high-fat diet (HFD-60, Oriental Yeast Company, Tokyo, Japan) and standard laboratory chow (see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} for the composition of each highly palatable diet). Total amounts of sucrose and fat consumption were calculated from each food type (i.e., sucrose and fat amounts from the white chocolate and from the high-fat diet) 25--48 hr after initial food exposure.

Immunohistochemistry for GFP and Fos immunoreactive cell expression {#s4-7}
-------------------------------------------------------------------

When data collection, outlined above, was complete mice were deeply anesthetized using chloral hydrate (500 mg/kg, i.p.) and perfused through the left ventricle of the heart with saline and subsequently perfused with neutral buffered 10% formalin solution. Brains were then removed and placed into vials containing 10% formalin solution for 1 week. Brains were subsequently transferred to vials containing 20% sucrose in phosphate-buffered saline (PBS) for 24 hr at 4°C to reduce freezing artifacts. Brains were then frozen using dry ice, placed on a freezing microtome and sectioned at 40 μm. Immunohistochemistry was undertaken on free floating brain sections as previously described ([@bib7]). In brief, sections were rinsed in PBS, incubated in 0.3% hydrogen peroxide in 0.25% Triton X-100 in PBS (PBT) for 30 min at room temperature, rinsed in PBS and incubated, overnight at room temperature, in rabbit GFP primary antibody (Molecular Probes, RRID:[AB_221569](https://scicrunch.org/resolver/AB_221569), lot number 1293114) at a dilution of 1:20,000 or rabbit Fos primary antibody (Millipore, RRID:[AB_2106755](https://scicrunch.org/resolver/AB_2106755), lot number D00058535) at a dilution of 1:20,000 in PBT with 0.02% sodium azide. After overnight incubation, brain sections were rinsed in PBS for 1 hr and then incubated for 90 min in biotinylated anti-rabbit antibody (Jackson ImmunoResearch) at a dilution of 1:1000. These sections were then treated with avidin-biotin complex (1:1000; Vectastain ABC Elite kit, Vector Labs) for 1 hr and immunoreactive cells were visualised by reaction with 3,3\'-diaminobenzidine and 0.01% hydrogen peroxide. Tissue sections mounted on glass slides were scanned with a Hamamatsu NanoZoomer-XR Digital slide scanner (Hamamatsu Photonics), and digital photomicrographs were analyzed with Hamamatsu NDPView software v2.4.26.

AAV location was assessed by visualizing GFP expression in brain sections using Hamamatsu NDPView software v2.4.26. Virus location figures (see [Figure 3](#fig3){ref-type="fig"}, Panel B and [Figure 4](#fig4){ref-type="fig"}, Panel A) were produced by using the following procedure: (a) observing virus location and spread within brain sections; (b) transforming digital photomicrographs images to color-scale images; and (c) superimposing these color-scale images to obtain a summation of AAV location for all mice.

Furthermore, Fos immunoreactive cell expression was measured using two AAV infused mice that were injected with either propylene glycol or IVM, exposed to the WMGD for 48 hr and fed a diet of white chocolate, HFD and chow. After WMGD exposure, mice were sacrificed during the dark period (i.e. at 21:00). Immunohistochemistry procedures were then undertaken as outlined above. Fos immunoreactive cell imaging, at 20 times magnification, was produced using Hamamatsu NDPView software v2.4.26 (see Panel C, [Figure 3](#fig3){ref-type="fig"}) by focusing on an area of interest located within the mPFC at 1.7 mm anterior and 0.4 mm lateral to bregma, and 2.0 mm below the dural surface.

Statistical analyses {#s4-8}
--------------------

Means and ± S.E.M. are expressed for all statistical comparisons. For comparisons between two groups, two-tailed paired samples Student's t-tests were used followed by Bonferroni corrections. In addition, Pearson correlations were used to compare associations between two groups. Repeated measures ANOVA or one-way ANOVA were used when comparing groups of three or more followed by Fisher's Probable Least-Squares Difference (PLSD) post hoc tests. For comparisons between independent samples, the Levene's test was used to assess homogeneity of variance and for paired sample comparisons the Mauchly's test was used to assess sphericity. All comparisons were considered statistically significant at p \< 0.05. Statistics for all data are reported in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.
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###### Composition of the highly palatable diets used in the feeding experiments.
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###### Statistics reported in this study.
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The following dataset was generated:

McEown K,Takata Y,Cherasse Y,Nagata N,Aritake K,Lazarus M,2016,Data from: Chemogenetic inhibition of the medial prefrontal cortex reverses the effects of REM sleep loss on sucrose consumption,<http://dx.doi.org/10.5061/dryad.4v58b>,Available at Dryad Digital Repository under a CC0 Public Domain Dedication
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Decision letter

Elmquist

Joel K

Reviewing editor

University of Texas Southwestern Medical Center

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Chemogenetic inhibition of the medial prefrontal cortex reverses the effects of REM sleep loss on sucrose consumption\" for consideration by *eLife*. Your article has been favorably evaluated by Timothy Behrens (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

McEown and colleagues describe results from a series of studies investigating the role of neurons in the medial prefrontal cortex (mPFC) in regulating and linking REM sleep to consumption of highly palatable food. They demonstrate that sleep loss induces an increase of a diet rich in sucrose. Notably, chemogenetic inhibition of mPFC neurons blunted that increase. They did not find an effect to blunt a high fat diet. Collectively, the results are novel and are potentially of wide interest. It is widely accepted that sleep disruption affects metabolism and energy balance. However, the CNS sites and mechanisms linking sleep disruption and obesity are poorly defined. However, as it currently stands the manuscript has several issues that need to be addressed.

Essential revisions:

The feeding studies are not well described and at this point seem somewhat preliminary. It is not clear if the mice were singly housed and how long they were acclimated to the diets and conditions. Also, it would be useful to know if the REM disruption paradigm affects body weight and composition over time. If this has been published it needs to be pointed out.

The authors allude to the fact that the mPFC neurons are affecting taste/palatability. Have previous studies investigated the role of these neurons in regulating taste?

Is this effect really specific for sucrose? By only having one comparison it is hard to judge the behavioral specificity of the PFC action.

The control of the effect of inactivation of the medial prefrontal cortex in basal condition on food consumption is missing. Indeed, it is important to verify whether the medial prefrontal cortex has also an effect in control condition. One question raised by the results is indeed whether the results are specific to the REM condition. It might be that the medial prefrontal cortex is indeed needed for sucrose consumption.

What is the difference between loss of REM in dark v. light period? Since the WMGD has the largest effect in the dark period, when mice are normally awake, the exact role of REM loss is a bit ambiguous. Some further clarification for how this works and that the mice do not catch up the light period would be helpful.

The authors used an original way to deprive mice of REM sleep. They put a wire mesh grid on the bottom of the mice cages. By this means, they obtained a significant decrease of REM sleep quantities during nighttime but not during the day. They also induced a small increase in wake quantities and a non-significant decrease in SWS quantities. I\'m wondering why they did not see an effect in the first 24h? This is not mentioned in the manuscript. They should also discuss why there is such a delayed onset of the effect? Also, how they explained it occurs only during the night?

10.7554/eLife.20269.013

Author response

*\[...\] Essential revisions:*

*The feeding studies are not well described and at this point seem somewhat preliminary. It is not clear if the mice were singly housed and how long they were acclimated to the diets and conditions. Also, it would be useful to know if the REM disruption paradigm affects body weight and composition over time. If this has been published it needs to be pointed out.*

We have added further detail to the feeding studies methods to better describe our experiments (please see subsection "HPF data collection"). Mice were singly housed and this point is now stated in the aforementioned subsection. Subjects were acclimated to the housing conditions for one week prior to introduction of the highly palatable diet or the wire-mesh-grid-device. Mice were not acclimated to the highly palatable diets prior to commencing the feeding studies and the REM disruption did not affect body weight over our 72 h testing period (please see subsection "GluClαβ-mPFC neuronal inhibition reverses the effect REM sleep loss on HPF consumption", last paragraph). We did not measure body composition over this 72 h period, however it is unlikely that our intervention would affect body composition (e.g., muscle, fat, etc.) over this short time period. We have not examined whether REM disruption, using our device, would affect body weight or composition over longer periods of time.

*The authors allude to the fact that the mPFC neurons are affecting taste/palatability. Have previous studies investigated the role of these neurons in regulating taste?*

Previous studies have investigated the role of mPFC neurons in regulating taste/palatability. We have added a few examples of this research as follows:

"More specifically, the anterior cingulate appears to mediate taste for glucose in primates as feeding fruit juice (i.e., a food high in glucose) to satiety decreased neuronal firing in the anterior cingulate cortex using single cell recordings, whereas initial juice feeding increased neuronal firing in these animals (Rolls et al. 2008). Chocolate flavor also increases activation, as measured by fMRI, in the anterior cingulate cortex in humans (Rolls and McCabe 2007)."

Is this effect really specific for sucrose? By only having one comparison it is hard to judge the behavioral specificity of the PFC action.

The mPFC may mediate the taste/palatability for other foods. Therefore, the effect of REM disruption may not be specific to only sucrose. Future research is needed to address this possibility. We have added sentences to the Discussion to address this possibility as follows:

"On the other hand, it is unknown whether consumption of other highly palatable foods may be effected by mPFC inactivation and/or REM disruption (e.g., foods high in salt content). Future research is needed to explore this possibility."

*The control of the effect of inactivation of the medial prefrontal cortex in basal condition on food consumption is missing. Indeed, it is important to verify whether the medial prefrontal cortex has also an effect in control condition. One question raised by the results is indeed whether the results are specific to the REM condition. It might be that the medial prefrontal cortex is indeed needed for sucrose consumption.*

We have now added these data to the text (subsection "GluClαβ-mPFC neuronal inhibition reverses the effect REM sleep loss on HPF consumption", third paragraph) and in a supplement to [Figure 4](#fig4){ref-type="fig"} (i.e., [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, Panel A). Our data show that the medial prefrontal cortex did not mediate sucrose consumption as non-sleep deprived medial prefrontal cortex inactivated mice did not differ in the amount of sucrose consumed compared to non-sleep deprived control mice.

*What is the difference between loss of REM in dark v. light period? Since the WMGD has the largest effect in the dark period, when mice are normally awake, the exact role of REM loss is a bit ambiguous. Some further clarification for how this works and that the mice do not catch up the light period would be helpful.*

It is unknown why REM disruption was confined to the dark period in our study. We have addressed these points as follows:

"It is unknown why our observed reduction in REM sleep was restricted to the dark phase and not during the light phase. Indeed, sleep pressure is greater during the light phase compared to the dark phase in mice, therefore it is possible that our device was only able to produce REM reduction during the dark phase when sleep pressure was weaker."

We have added a supplement to [Figure 1](#fig1){ref-type="fig"} (i.e., [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) showing that REM sleep does not rebound during the first three hours of the light period 25-48 h after WMGD introduction. We have also addressed this in text (subsection "Wire-mesh-grid device exposure produced REM sleep loss", first paragraph).

*The authors used an original way to deprive mice of REM sleep. They put a wire mesh grid on the bottom of the mice cages. By this means, they obtained a significant decrease of REM sleep quantities during nighttime but not during the day. They also induced a small increase in wake quantities and a non-significant decrease in SWS quantities. I\'m wondering why they did not see an effect in the first 24h? This is not mentioned in the manuscript. They should also discuss why there is such a delayed onset of the effect? Also, how they explained it occurs only during the night?*

Indeed, we do not know why our device successfully reduced REM sleep during the dark period but not during the light period. However, we have addressed this point in the third paragraph of the Discussion. In addition, we have addressed the delayed onset of the REM effect as follows:

"In addition, the REM sleep disruption observed in the current investigation did not occur during the first 24 h after WMGD introduction. A plausible explanation is that the sleep reducing effect of our device requires time to build-up and thus produce disturbances in sleep."
